People · Operator
Named in public records as an officer, director or promoter · active 2025–2025 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Protego Biopharma | — | Biotechnology | Series C | $85.0M | $179.4M | 2025 |
SAOUSSEN J. BEN HALIMA at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside SAOUSSEN J. BEN HALIMA on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Shelley Chu | 1 | 10 |
| SHELLEY J. CHU | 1 | 2 |
| HELEN J. KIM | 1 | 2 |
| Jeffery W. Kelly | 1 | 2 |
| Brent J. Warner | 1 | 2 |
| Edward Hurwitz | 1 | 2 |
| EDWARD J. HURWITZ | 1 | 2 |
| Helen Kim | 1 | 2 |
| Jeffrey Kelly | 1 | 2 |
| Edward W Hurwitz | 1 | 1 |
| TIM J. LOHOFF | 1 | 1 |
| HANK MICHAEL PETRASSI | 1 | 1 |
| JANWILLEM J. NAESENS | 1 | 1 |
| LAURA J. BRASS | 1 | 1 |
| JEFFERY J. KELLY | 1 | 1 |
| Richard Labaudiniere | 1 | 1 |
| XIN JIANG | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.